The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Targeting the nucleolus for cancer intervention
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“and the new-generation ‘rapalog’ everolimus, which is FDA-approved for the treatment of renal cell carcinoma and advanced ER-positive/ HER2-negative breast cancer [247,248], displays potent anti-tumor activity in a MYC-driven lymphoma model characterized by enhanced Pol I transcription [1,249].”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“and the new-generation ‘rapalog’ everolimus, which is FDA-approved for the treatment of renal cell carcinoma and advanced ER-positive/ HER2-negative breast cancer [247,248], displays potent anti-tumor activity in a MYC-driven lymphoma model characterized by enhanced Pol I transcription [1,249].”
BackgroundRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“Further, downstream targets of p53-dependent stress signaling also negatively regulate Pol I transcription, including activation of pRb (reviewed in [86]), or repression of MYC [87].”
BackgroundZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 2×
“Further, posttranslational modification and association with co-factors mediate p53 activity towards its transcriptional targets (reviewed in [129,130]).”
BackgroundPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“Correspondingly, p53 is mutated in approximately half of all human tumors [84], and in the”
BackgroundReflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×
“MYC regulates transcription of a large cohort of genes particularly those which drive cell growth, including key factors involved in ribosome biogenesis and protein synthesis [45] and [46] (reviewed in [47], [48], [49] and [50]).”
BackgroundDang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Signaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591
Life on a planet of its own: Regulation of RNA polymerase I transcription in the nucleolus
Grummt, I. (2003) · Genes & Development · doi:10.1101/gad.1098503r · Cited by 540
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442 · cited 1×
“Loss of p14ARF is almost as common as loss of p53, occurring in as many as 40% of human cancers (reviewed in [92,93]).”
BackgroundLødrup Carlsen, K. C., Roll, S., Carlsen, K.-H., Mowinckel, P., Wijga, A. H., Brunekreef, B., Torrent, M., Roberts, G., Arshad, S. H., Kull, I., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043214 · Cited by 400
The ATM repair pathway inhibits RNA polymerase I transcription in response to chromosome breaks
Kruhlak, M., Crouch, E. E., Orlov, M., Montaño, C., Gorski, S. A., Nussenzweig, A., Misteli, T., Phair, R. D., & Casellas, R. (2007) · Nature · doi:10.1038/nature05842 · Cited by 305
Repression of RNA Polymerase I Transcription by the Tumor Suppressor p53
Zhai, W., & Comai, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5930-5938.2000 · Cited by 289 · cited 10×
“The search for the next generation of direct Pol I inhibitors yielded the lead compound CX5461 (now owned by Senhwa Biosciences), a small molecule that prevents PIC assembly by interfering with SL-1 binding to the rDNA promoter thereby preventing transcription initiation [189] (Figure 4).”
BackgroundInfluentialRapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., & Pearson, R. B. (2007) · Growth Factors · doi:10.1080/08977190701779101 · Cited by 240 · cited 1×
“[76] [77] and [78] (reviewed in [79] and [80]).”
The Role of Myc-Induced Protein Synthesis in Cancer
Ruggero, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1970 · Cited by 186 · cited 1×
“MYC regulates transcription of a large cohort of genes particularly those which drive cell growth, including key factors involved in ribosome biogenesis and protein synthesis [45] and [46] (reviewed in [47], [48], [49] and [50]).”
BackgroundBoisvert, F.-M., Lam, Y. W., Lamont, D., & Lamond, A. I. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900429-mcp200 · Cited by 185
Guetg, C., Lienemann, P., Sirri, V., Grummt, I., Hernandez‐Verdun, D., Hottiger, M. O., Fussenegger, M., & Santoro, R. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.17 · Cited by 184
Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA.
Froelich-Ammon, S. J., Patchan, M. W., Osheroff, N., & Thompson, R. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.14998 · Cited by 137 · cited 1×
“historically proposed to be the result of DNA breakage following the formation of an ellipticine–topoisomerase II–DNA ternary complex [237].”
BackgroundRegulation of nucleolar signalling to p53 through NEDDylation of L11
Sundqvist, A., Liu, G., Mirsaliotis, A., & Xirodimas, D. P. (2009) · The EMBO Reports · doi:10.1038/embor.2009.178 · Cited by 132
Epigenetic control of RNA polymerase I transcription in mammalian cells
Grummt, I., & Längst, G. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.10.004 · Cited by 132 · cited 1×
“transcriptionally silenced, with a heavily CpG methylated heterochromatic structure (H3K9Me, HK27Me and H3K20Me) (reviewed in [11], [12], [13], [14] and [15]).”
Backgroundc-Myc induces changes in higher order rDNA structure on stimulation of quiescent cells
Shiue, C.-N., Berkson, R. G., & Wright, A. P. H. (2009) · Oncogene · doi:10.1038/onc.2009.21 · Cited by 69
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Self-citation
Cited by
Metal complex interactions with DNA
Pages, B. J., Ang, D. L., Wright, E. P., & Aldrich-Wright, J. R. (2015) · Dalton Transactions · doi:10.1039/c4dt02700k · Cited by 459
Baßler, J., & Hurt, E. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-110817 · Cited by 414
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
Self-citationHua, X.-W., Bao, Y.-W., & Wu, F.-G. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b19549 · Cited by 339
Nucleolar stress with and without p53
James, A., Wang, Y., Raje, H., Rosby, R., & DiMario, P. (2014) · Nucleus · doi:10.4161/nucl.32235 · Cited by 285
Metadata
- Authors
- Quin, J. E., Devlin, J. R., Cameron, D., Hannan, K. M., Pearson, R. B., & Hannan, R. D.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 1842
- Issue
- 6
- Pages
- 802-816
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W1981188497
- Cited by
- 226
- References
- 30
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.